Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Blog
July 30, 2026
Cross-linking fails to halt progression in a minority of eyes, more often in younger patients and in advanced or rapidly changing corneas. Repeat cross-linking is possible, and newer thinking looks at what keeps driving the cornea: eye rubbing, allergy, inflammation and sleep apnea. This page explains what to check when it keeps moving.
For years, people diagnosed with keratoconus were told the same thing: their corneas were structurally weak. The progressive eye disease, which causes the cornea to thin and bulge outward, was treated as a mechanical problem, managed with rigid contact lenses, surgical implants, or a procedure called corneal cross-linking that stiffens corneal tissue. But scientists are now rethinking that explanation.
A growing body of research suggests keratoconus may not be simply a structural defect at all. Studies of tear fluid and corneal tissue find raised inflammatory markers in keratoconus, even though the eye does not look inflamed. People with keratoconus are also more likely than others to have several immune-related conditions (Claessens 2022). Whether this inflammation drives the disease is not yet known.
That shift in understanding could explain why some patients continue to lose vision despite receiving standard treatments and why new approaches are beginning to focus on inflammation rather than shape alone.
Keratoconus does not usually cause redness, swelling, or pain. That’s one reason it was long considered non-inflammatory. But modern laboratory techniques tell a different story.
Studies examining tear fluid and corneal tissue in keratoconus patients consistently find elevated levels of inflammatory molecules, known as cytokines. These include interleukin-6, tumor necrosis factor-alpha, and other immune signals commonly associated with tissue Damage.
Researchers have also found that higher levels of these inflammatory markers often correlate with more severe disease. In other words, while the eye may look calm on the surface, immune activity beneath it appears to be quietly weakening corneal tissue over time.
The cornea maintains its strength through a precisely organized collagen framework. Chronic inflammation disrupts this framework by activating enzymes that break down collagen faster then the eye can repair it.
Mechanical stress, such as frequent eye rubbing, often associated with allergies or dry eye, can intensify the inflammatory response. Each episode of rubbing triggers additional cytokine release, creating a feedback loop that accelerates corneal thinning and distortion. Over months or years, this process leads to the cone-shaped bulging that defines keratoconus.
Inflammation is only part of the story. Researchers have also identified oxidative stress, a form of cellular damage caused by unstable oxygen molecules, as a major contributor to Keratoconus.
In healthy eyes, antioxidants neutralize these molecules.In keratoconus patients, antioxidant defenses appear impaired, allowing damage to accumulate. This environment can trigger ferroptosis, a recently recognized form of cell death that destroys corneal cells essential for maintaining tissue strength. Together, inflammation and oxidative stress create conditions in which the cornea steadily loses its ability to maintain its shape.
Corneal collagen cross-linking remains one of the most widely used treatments for keratoconus. By stiffening collagen fibers, it can slow disease progression for many patients.
Cross-linking stops progression in most treated eyes, but not all. In a Swiss series of 117 eyes, keratoconus kept progressing after treatment in 7.6%, more often when the cornea was very steep to begin with (Koller 2009). In children, reported rates range from 4% to 35%, depending on how progression is measured (Buzzonetti 2026). Some researchers suggest that ongoing inflammation or eye rubbing may play a part, but this has not been proven. If scans show continued change, repeat cross-linking may be an option.
Corneal Cytokine Regulation (CCR) is the name Netra Eye Institute gives to the inflammation-focused part of Netra Restoration Therapy (NRT) for people with keratoconus. Its aim is to lower the everyday sources of inflammation and mechanical stress around the cornea. It works alongside your cornea specialist’s care, never instead of it.
What CCR works on:
What CCR is not:
The newest approved treatment is epithelium-on cross-linking. In October 2025 the FDA approved Epioxa, which strengthens the cornea without removing its surface layer (FDA approval record; prescribing information). Researchers are also studying inflammation in keratoconus, but no anti-inflammatory treatment has yet been shown to slow it.
Possibly, but it is not proven. Inflammatory markers are raised in keratoconus, and eye rubbing and allergy are linked to it. Whether calming inflammation slows keratoconus has not been tested in trials.
Cross-linking stops progression in most treated eyes, but not all. Very steep corneas and younger patients are more likely to keep progressing (Koller 2009; Buzzonetti 2026). If scans show continued change, your cornea specialist may suggest repeat cross-linking.
There are no clinical trials of either in keratoconus. They can be used alongside regular scans to work on itch, allergy, rubbing and stress, but not to change the cornea itself.
If your keratoconus is still progressing, see your cornea specialist first; repeat cross-linking may be an option. Inflammation-focused care is most relevant if you have ongoing eye rubbing, allergy or dry eye, as support alongside that care.
